Crossmark Global Holdings Inc. Sells 13,829 Shares of Humana Inc. $HUM

Crossmark Global Holdings Inc. reduced its stake in shares of Humana Inc. (NYSE:HUM) by 63.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,055 shares of the insurance provider’s stock after selling 13,829 shares during the period. Crossmark Global Holdings Inc.’s holdings in Humana were worth $2,096,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in shares of Humana by 7.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,248,989 shares of the insurance provider’s stock valued at $324,870,000 after acquiring an additional 84,374 shares during the period. Insigneo Advisory Services LLC raised its stake in Humana by 3.0% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock worth $386,000 after acquiring an additional 43 shares during the period. Cresset Asset Management LLC raised its stake in Humana by 1,736.8% during the 3rd quarter. Cresset Asset Management LLC now owns 43,513 shares of the insurance provider’s stock worth $11,359,000 after acquiring an additional 41,144 shares during the period. Focus Partners Advisor Solutions LLC lifted its holdings in Humana by 26.2% during the third quarter. Focus Partners Advisor Solutions LLC now owns 3,158 shares of the insurance provider’s stock valued at $802,000 after purchasing an additional 655 shares in the last quarter. Finally, Kingsview Wealth Management LLC lifted its holdings in Humana by 18.4% during the third quarter. Kingsview Wealth Management LLC now owns 14,507 shares of the insurance provider’s stock valued at $3,774,000 after purchasing an additional 2,257 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Sanjay K. Shetty purchased 810 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was bought at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the purchase, the insider owned 11,657 shares in the company, valued at approximately $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.37% of the company’s stock.

Humana Trading Down 0.8%

Humana stock opened at $179.27 on Monday. Humana Inc. has a 1 year low of $169.61 and a 1 year high of $315.35. The firm’s 50 day moving average price is $221.75 and its 200-day moving average price is $252.00. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00. The stock has a market cap of $21.62 billion, a P/E ratio of 18.26, a PEG ratio of 1.93 and a beta of 0.44.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. Humana’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Friday, March 27th. Humana’s payout ratio is currently 36.05%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HUM. Barclays reduced their price objective on shares of Humana from $245.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Humana in a research note on Thursday, January 22nd. Cantor Fitzgerald dropped their target price on shares of Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a report on Thursday, February 12th. Robert W. Baird cut their price target on Humana from $280.00 to $264.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. Finally, Jefferies Financial Group decreased their price target on Humana from $310.00 to $235.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $225.48.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.